Cancer immunoediting hypothesis: history, clinical implications and controversies

被引:17
作者
Lasek, Witold [1 ]
机构
[1] Med Univ Warsaw, Dept Immunol, Warsaw, Poland
关键词
tumor immunology; cancer immunoediting; immune contexture; TUMOR-INFILTRATING LYMPHOCYTES; IFN-GAMMA; T-CELLS; GROWTH; PERFORIN; IMMUNITY; SURVEILLANCE; IMMUNOLOGY; HALLMARKS; PROTEINS;
D O I
10.5114/ceji.2022.117376
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The main function of the immune system is to protect against infectious pathogens and to ensure tissue homeostasis. The latter function includes preventing autoimmune reactions, tolerizing cells to nonpathogenic environmental microorganisms, and eliminating apoptotic/damaged, transformed, or neoplastic cells. The process of carcinogenesis and tumor development and the role of the immune system in inhibiting progression of cancer have been the subject of intense research since the end of the 200 century and resulted in formulation of the cancer immunoediting hypothesis. The hypothesis postulates three steps in oncogenesis: 1) elimination - corresponding to immunosurveillance, 2) equilibrium in which the growth of transformed or neoplastic cells is efficiently controlled by immune effector mechanisms, and 3) escape in which cancer progresses due to an ineffective antitumor response. In parallel, a new field of science - immune-oncology - has arisen. Attempts are also being made to quantify intra-tumoral and peritumoral T cell infiltrations and to define optimal immunological parameters for prognostic/predictive purposes in several types of cancer. The knowledge of relationships between the tumor and the immune system has been and is practically exploited therapeutically in the clinic to treat cancer. Immunotherapy is a standard or supplementary treatment in various types of cancer.
引用
收藏
页码:168 / 174
页数:7
相关论文
共 83 条
  • [1] From the immune contexture to the Immunoscore: the role of prognostic and predictive immune markers in cancer
    Angel, Helen
    Galon, Jerome
    [J]. CURRENT OPINION IN IMMUNOLOGY, 2013, 25 (02) : 261 - 267
  • [2] The Immunoscore: Colon Cancer and Beyond
    Angell, Helen K.
    Bruni, Daniela
    Barrett, J. Carl
    Herbst, Ronald
    Galon, Jerome
    [J]. CLINICAL CANCER RESEARCH, 2020, 26 (02) : 332 - 339
  • [3] Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance
    Bagchi, Sreya
    Yuan, Robert
    Engleman, Edgar G.
    [J]. ANNUAL REVIEW OF PATHOLOGY: MECHANISMS OF DISEASE, VOL 16, 2021, 2021, 16 : 223 - 249
  • [4] Historical Overview of Transplantation
    Barker, Clyde F.
    Markmann, James F.
    [J]. COLD SPRING HARBOR PERSPECTIVES IN MEDICINE, 2013, 3 (04):
  • [5] Growth factors and cytokines in wound healing
    Barrientos, Stephan
    Stojadinovic, Olivera
    Golinko, Michael S.
    Brem, Harold
    Tomic-Canic, Marjana
    [J]. WOUND REPAIR AND REGENERATION, 2008, 16 (05) : 585 - 601
  • [6] Mutations of the β2-microglobulin gene result in a lack of HLA class I molecules on melanoma cells of two patients immunized with MAGE peptides
    Benitez, R
    Godelaine, D
    Lopez-Nevot, MA
    Brasseur, F
    Jiménez, P
    Marchand, M
    Oliva, MR
    van Baren, N
    Cabrera, T
    Andry, G
    Landry, C
    Ruiz-Cabello, F
    Boon, T
    Garrido, F
    [J]. TISSUE ANTIGENS, 1998, 52 (06): : 520 - 529
  • [7] Tumor antigens recognized by T cells
    Boon, T
    Coulie, PG
    VandenEynde, B
    [J]. IMMUNOLOGY TODAY, 1997, 18 (06): : 267 - 268
  • [8] The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy
    Bruni, Daniela
    Angell, Helen K.
    Galon, Jerome
    [J]. NATURE REVIEWS CANCER, 2020, 20 (11) : 662 - 680
  • [9] BURNET FM, 1970, PROG EXP TUMOR RES, V13, P1
  • [10] Clemente CG, 1996, CANCER, V77, P1303, DOI 10.1002/(SICI)1097-0142(19960401)77:7<1303::AID-CNCR12>3.3.CO